Alix E Seif

List of Publications by Year
in descending order

138 papers	3,824 citations	159525 30 h-index	133188 59 g-index
141 all docs	141 docs citations	141 times ranked	6493 citing authors

#	Article	IF	Citations
1	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood, 2013, 121, 5154-5157.	0.6	524
2	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications, 2016, 7, 12320.	5.8	325
3	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARSâ€“CoV-2. Journal of Clinical Investigation, 2020, 130, 5967-5975.	3.9	319
4	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2012, 120, 3510-3518.	0.6	263
5	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood, 2016, 127, 17-28.	0.6	165
6	Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. British Journal of Haematology, 2009, 145, 101-106.	1.2	151
7	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood, 2008, 112, 2020-2023.	0.6	117
8	Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). British Journal of Haematology, 2010, 148, 205-216.	1.2	115
9	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 556-556.	0.6	106
10	Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood, 2010, 115, 2142-2145.	0.6	84
11	Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genetics, 2011, 204, 227-244.	0.2	79
12	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric Tâ€cell lymphoblastic leukaemia and lymphoma. British Journal of Haematology, 2010, 150, 345-351.	1.2	74
13	Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood, 2008, 111, 705-714.	0.6	68
14	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatric Blood and Cancer, 2015, 62, 704-709.	0.8	65
15	Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States. Journal of Pediatrics, 2013, 162, 1252-1258.e1.	0.9	53
16	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood, 2011, 118, e112-e117.	0.6	49
17	Outcome of Pediatric Acute Myeloid Leukemia Patients Receiving Intensive Care in the United States. Pediatric Critical Care Medicine, 2014, 15, 112-120.	0.2	48
18	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 1537-1543.	0.8	47

#	Article	IF	Citations
19	Merging of the National Cancer Instituteâ€“funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiology and Drug Safety, 2012, 21, 37-43.	0.9	44
20	A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Childrenâ€™s Oncology Group study ANBL00P1. Bone Marrow Transplantation, 2013, 48, 947-952.	1.3	43
21	Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Childrenâ€™s Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data. Medical Care, 2014, 52, e1-e6.	1.1	42
22	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatric Blood and Cancer, 2019, 66, e27747.	0.8	40
23	The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 71, 3044-3054.	2.9	38
24	Induction mortality and resource utilization in children treated for acute myeloid leukemia at freeâ€standing pediatric hospitals in the United States. Cancer, 2013, 119, 1916-1923.	2.0	37
25	Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood, 2009, 114, 2459-2466.	0.6	36
26	Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplantation, 2016, 51, 1204-1210.	1.3	36
27	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research, 2008, 42, 84-105.	1.3	35
28	Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database. Pediatric Blood and Cancer, 2013, 60, 616-620.	0.8	35
29	Assembly of a cohort of children treated for acute myeloid leukemia at freeâ€standing children's hospitals in the United States using an administrative database. Pediatric Blood and Cancer, 2013, 60, 508-511.	0.8	33
30	Using electronic medical record data to report laboratory adverse events. British Journal of Haematology, 2017, 177, 283-286.	1.2	31
31	Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. Journal of Experimental Medicine, 2021, 218, .	4.2	31
32	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. American Journal of Hematology, 2017, 92, 141-148.	2.0	29
33	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene, 2019, 38, 2241-2262.	2.6	29
34	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Childrenâ€™s Hospitals. JAMA Pediatrics, 2014, 168, 925.	3.3	24
35	Nutritional risk factors predict severe acute graftâ€versusâ€host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2018, 65, e26853.	0.8	22
36	Outcomes of Human Adenovirus Infection and Disease in a Retrospective Cohort of Pediatric Hematopoietic Cell Transplant Recipients. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 317-324.	0.6	22

#	Article	IF	Citations
37	Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 1633-1639.	0.6	21
38	Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2014, 61, 846-852.	0.8	21
39	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1775-1781.	0.8	21
40	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. Leukemia and Lymphoma, 2019, 60, 2190-2198.	0.6	21
41	Variation in Risk of Hospital-Onset Clostridium difficile Infection Across Â-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 329-335.	0.6	18
42	Antifungal Prophylaxis Associated With Decreased Induction Mortality Rates and Resources Utilized in Children With New-Onset Acute Myeloid Leukemia. Clinical Infectious Diseases, 2014, 58, 502-508.	2.9	18
43	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Medicine, 2015, 4, 1356-1364.	1.3	17
44	Veno-occlusive disease after high-dose busulfanâ€“melphalan in neuroblastoma. Bone Marrow Transplantation, 2020, 55, 531-537.	1.3	17
45	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	3.2	17
46	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. PLoS ONE, 2018, 13, e0192529.	1.1	16
47	Merging Childrenâ€™s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Childrenâ€™s Oncology Group. PLoS ONE, 2015, 10, e0143480.	1.1	16
48	Establishing a highâ€risk neuroblastoma cohort using the pediatric health information system database. Pediatric Blood and Cancer, 2014, 61, 1129-1131.	0.8	15
49	Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses. Leukemia, 2016, 30, 2116-2119.	3.3	15
50	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. Blood, 2011, 118, 4242-4242.	0.6	15
51	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at freeâ€standing paediatric hospitals in the United States. British Journal of Haematology, 2016, 174, 591-599.	1.2	14
52	Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia, 2020, 34, 1741-1750.	3.3	14
53	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Leukemia and Lymphoma, 2016, 57, 1567-1574.	0.6	13
54	IFNâ€Î³ directly inhibits murine Bâ€cell precursor leukemiaâ€initiating cell proliferation early in life. European Journal of Immunology, 2017, 47, 892-899.	1.6	13

#	Article	IF	Citations
55	Cost comparison by treatment arm and centerâ€level variations in cost and inpatient days on the phase <scp>III</scp> highâ€risk B acute lymphoblastic leukemia trial <scp>AALL</scp>0232. Cancer Medicine, 2018, 7, 3-12.	1.3	13
56	Comparison of administrative/billing data to expected protocolâ€mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1184-1189.	0.8	12
57	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 223-229.e2.	0.2	12
58	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatric Blood and Cancer, 2014, 61, 68-73.	0.8	11
59	Volumeâ€“Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 404-410.e1.	0.2	11
60	Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9. Biology of Blood and Marrow Transplantation, 2020, 26, 1266-1272.	2.0	11
61	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatric Blood and Cancer, 2021, 68, e29026.	0.8	11
62	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. Pediatric Critical Care Medicine, 2018, 19, e312-e320.	0.2	10
63	Comparable onâ€therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2019, 66, e27583.	0.8	10
64	Immune Reconstitution Following TCRÎ±Î²/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. Transplantation and Cellular Therapy, 2021, 27, 169.e1-169.e9.	0.6	9
65	Unrelated donor Î±Î² T cellâ€“ and B cellâ€“depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances, 2022, 6, 1175-1185.	2.5	9
66	Intrathecal Liposomal Cytarabine in Relapsed or Refractory Infant and Pediatric Leukemias: The Children's Hospital of Philadelphia Experience and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2010, 32, e349-e352.	0.3	8
67	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Pediatric Blood and Cancer, 2016, 63, 901-907.	0.8	8
68	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. Cancer, 2016, 122, 3394-3400.	2.0	8
69	Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1052-1054.e2.	2.0	8
70	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Pediatric Blood and Cancer, 2022, 69, e29384.	0.8	8
71	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 290-296.	0.6	7
72	Outcomes of matched sibling donor bone marrow transplantation in children using singleâ€agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatric Blood and Cancer, 2018, 65, e26726.	0.8	7

#	Article	IF	Citations
73	Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. Pediatric Transplantation, 2019, 23, e13510.	0.5	7
74	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. PLoS ONE, 2016, 11, e0151362.	1.1	5
75	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. PLoS ONE, 2017, 12, e0186960.	1.1	5
76	Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy, 2018, 67, 225-236.	2.0	5
77	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. Cancers, 2020, 12, 169.	1.7	5
78	Early discharge as a mediator of greater <scp>ICU</scp>â€level care requirements in patients not enrolled on the <scp>AAML</scp>0531 clinical trial: a Children's Oncology Group report. Cancer Medicine, 2016, 5, 2412-2416.	1.3	4
79	Complications preceding early deaths in Black and White children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26712.	0.8	4
80	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2017, 102, e340-e343.	1.7	4
81	Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia. Leukemia, 2018, 32, 539-542.	3.3	4
82	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in highâ€risk neuroblastoma using a national administrative database. Pediatric Blood and Cancer, 2018, 65, e27372.	0.8	4
83	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 684-688.	1.2	4
84	Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29467.	0.8	4
85	Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy. Pediatric Blood and Cancer, 2010, 55, 386-389.	0.8	3
86	Zoonotic infections in pediatric patients with acute leukemia. Pediatric Blood and Cancer, 2013, 60, E160-E162.	0.8	3
87	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2020, 26, 493-501.	2.0	3
88	Minimal Residual Disease Risk-Stratification in Pediatric Mixed Phenotype Acute Leukemia: Results of a Multi-Center Cohort Study. Blood, 2018, 132, 558-558.	0.6	3
89	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 369-369.	0.6	3
90	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. Blood, 2013, 122, 330-330.	0.6	2

#	Article	IF	Citations
91	Optimized amplification of BK polyomavirus in urine. Journal of Virological Methods, 2022, 299, 114319.	1.0	2
92	Newborn Screening for SCID Is Associated with a Shorter Interval from Diagnosis to Transplant. Journal of Allergy and Clinical Immunology, 2016, 137, AB218.	1.5	1
93	Favorable Chronic Graft-Versus-Host-Disease (GVHD), Event-Free (EFS), and Overall Survival (OS) Rates Following Partially CD3-Depleted Alternative Donor Peripheral Stem Cell Transplantation (PSCT) for Pediatric Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, S62-S63.	2.0	1
94	Low Body Mass Index and a Composite Nutritional Risk Variable Predict High-Grade Acute Graft-Versus-Host Disease (aGVHD) and Early Mortality in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). Biology of Blood and Marrow Transplantation, 2016, 22, S259-S260.	2.0	1
95	The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant. Bone Marrow Transplantation, 2018, 53, 938-941.	1.3	1
96	BK Viremia is Common in Children after Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, S87.	2.0	1
97	Transient atypical monocytosis after Î±/Î² Tâ€cellâ€depleted haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28139.	0.8	1
98	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatric Blood and Cancer, 2021, 68, e28315.	0.8	1
99	BK Polyomavirus (BKPyV) Infects and Injures Endothelium after Pediatric Hematopoietic Cell Transplant (HCT). Transplantation and Cellular Therapy, 2021, 27, S359-S361.	0.6	1
100	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatric Blood and Cancer, 2021, 68, e28940.	0.8	1
101	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 703-703.	0.6	1
102	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. Blood, 2010, 116, 2140-2140.	0.6	1
103	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). Blood, 2013, 122, 1689-1689.	0.6	1
104	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999â€“2009. Blood, 2010, 116, 3239-3239.	0.6	1
105	Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States. Blood, 2012, 120, 4278-4278.	0.6	1
106	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	0.6	1
107	Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO. Blood, 2021, 138, 4475-4475.	0.6	1
108	Heritable predisposition to childhood hematologic malignancies. , 0, , 276-308.		0

#	Article	IF	Citations
109	439Infection Risk in Pediatric Stem Cell Transplant Recipients for Hemophagocytic Lymphohistiocytosis vs Acute Leukemia. Open Forum Infectious Diseases, 2014, 1, S167-S167.	0.4	0
110	Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Using TCR Î±Î²+CD3+Depletion in Pediatric Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, S244-S245.	2.0	0
111	Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL) in First Remission (CR1): A Single-Institution Retrospective Cohort Study Demonstrating Excellent Event-Free (EFS) and Overall Survival (OS). Biology of Blood and Marrow Transplantation, 2016, 22, S238-S239.	2.0	0
112	Predicting Optimal Timing of Halting IVIG Therapy after HSCT for SCID. Journal of Allergy and Clinical Immunology, 2016, 137, AB276.	1.5	0
113	Single-Agent Calcineurin-Inhibitor (CNI) for the Prevention of Graft Versus Host Disease (GVHD) in Pediatric Patients Undergoing HLA-Identical Sibling Bone Marrow Transplant (BMT). Biology of Blood and Marrow Transplantation, 2017, 23, S366.	2.0	0
114	Immune Reconstitution In Six Adolescents With Chronic Granulomatous Disease (CGD) Following Hematopoietic Stem Cell Transplant (HSCT). Journal of Allergy and Clinical Immunology, 2017, 139, AB111.	1.5	0
115	Comparative Effectiveness of Cidofovir Preemptive Therapy for Human Adenovirus Infection in Pediatric Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2017, 4, S715-S715.	0.4	0
116	1762. Genotype Prevalence and Molecular Characteristics of Human Adenovirus in Pediatric Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, S648-S649.	0.4	0
117	Celiac Disease Risk Determined By HLA-DQ Genotype Protects Against Gvhd in a Dose-Responsive Manner. Biology of Blood and Marrow Transplantation, 2020, 26, S186.	2.0	0
118	Extracellular Vesicle Proteome Reflects BK Viral Infection and Cystitis Status in Pediatric Hematopoietic Stem Cell Transplant (HSCT) Recipients. Transplantation and Cellular Therapy, 2021, 27, S355-S356.	0.6	0
119	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2830-2830.	0.6	0
120	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617.	0.6	0
121	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	0.6	0
122	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3540-3540.	0.6	0
123	Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models.. , 2013, , .		0
124	Abstract B33: Toll-like receptor ligands delay acute lymphoblastic leukemia onset via depletion of pre-leukemic cells. , 2014, , .		0
125	Abstract B20: Innate and adaptive immune control of neoantigen-bearing acute lymphoblastic leukemia (ALL) enhanced by epitope spread. , 2014, , .		0
126	Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia. Blood, 2014, 124, 3697-3697.	0.6	0

#	Article	IF	Citations
127	Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2653-2653.	0.6	0
128	ÂResource Utilization and Cost Analysis By Treatment Arm on the Childrenâ€™s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 210-210.	0.6	0
129	Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3717-3717.	0.6	0
130	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 2286-2286.	0.6	0
131	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	0.6	0
132	Abstract A51: Early-life infection delays B cell precursor leukemia onset in Eu-Ret mice via an IL-23-dependent depletion of leukemia-initiating cells. , 2017, , .		0
133	Renal Complications Associated with HSCT. , 2018, , 327-332.		0
134	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	0.6	0
135	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. Blood, 2018, 132, 3597-3597.	0.6	0
136	Clinical Outcomes in Pediatric Mixed Phenotype Acute Leukemia (MPAL) Differ Depending on Disease Classification Criteria; A Multi-Center Cohort Study. Blood, 2018, 132, 4080-4080.	0.6	0
137	Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS). Blood, 2019, 134, 3496-3496.	0.6	0
138	BK Polyomavirus Subtypes II and IV in Hematopoietic Cell Transplant Recipients. Microbiology Resource Announcements, 2022, 11, e0105321.	0.3	0